Hypoxia decreases sclerostin expression and increases Wnt signaling in osteoblasts

Journal of Cellular Biochemistry

Volumn 110, Issue 2, 2010, Pages 457-467

  Genetos, Damian C ^a   Toupadakis, Chrisoula A ^a   Raheja, Leah F ^a   Wong, Alice ^a   Papanicolaou, Savvas E ^a   Fyhrie, David P ^a   Loots, Gabriela G ^b   Yellowley, Clare E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LAWRENCE LIVERMORE NATIONAL LABORATORY   (United States)

Author keywords

Bone morphogenetic protein; Hypoxia; Osteoblast; Sclerostin; Sost; Wnt

Indexed keywords

BETA CATENIN; BONE MORPHOGENETIC PROTEIN 12; NOGGIN; OXYGEN; PROCOLLAGEN C PROTEINASE; SCLEROSTIN; SMAD1 PROTEIN; SMAD5 PROTEIN; SMAD8 PROTEIN; VASCULOTROPIN; WNT PROTEIN;

ARTICLE; CELL CULTURE; CELL HYPOXIA; CONTROLLED STUDY; GENETIC TRANSCRIPTION; HYPOXIA; NUCLEAR LOCALIZATION SIGNAL; OSTEOBLAST; OSTEOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REPORTER GENE; SIGNAL TRANSDUCTION;

BETA CATENIN; BLOTTING, WESTERN; BONE MORPHOGENETIC PROTEINS; CELL HYPOXIA; CELL LINE; GENETIC MARKERS; HUMANS; OSTEOBLASTS; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WNT PROTEINS;

EID: 77952027256     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.22559     Document Type: Article

References (44)

1. Babij P, Zhao W, Small C, Kharode Y, Yaworsky PJ, Bouxsein ML, Reddy PS, Bodine PV, Robinson JA, Bhat B, Marzolf J, Moran RA, Bex F. 2003. High bone mass in mice expressing a mutant LRP5 gene. J Bone Miner Res 18:960-974. (Pubitemid 37294932)
2. Balemans W, Van Den Ende J, Freire Paes-Alves A, Dikkers FG, Willems PJ, Vanhoenacker F, de Almeida-Melo N, Alves CF, Stratakis CA, Hill SC, Van Hul W. 1999. Localization of the gene for sclerosteosis to the van Buchem disease-gene region on chromosome 17q12-q21. Am J Hum Genet 64:1661-1669. (Pubitemid 30481518)
3. Balemans W, Ebeling M, Patel N, Van Hul E, Olson P, Dioszegi M, Lacza C, Wuyts W, Van Den Ende J, Willems P, Paes-Alves AF, Hill S, Bueno M, Ramos FJ, Tacconi P, Dikkers FG, Stratakis C, Lindpaintner K, Vickery B, Foernzler D, Van Hul W. 2001. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 10:537-543. (Pubitemid 32184286)
4. Bellido T, Ali AA, Gubrij I, Plotkin LI, Fu Q, O'Brien CA, Manolagas SC, Jilka RL. 2005. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: A novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 146:4577-4583. (Pubitemid 41446595)
5. Costello CM, Howell K, Cahill E, McBryan J, Konigshoff M, Eickelberg O, Gaine S, Martin F, McLoughlin P. 2008. Lung-selective gene responses to alveolar hypoxia: Potential role for the bone morphogenetic antagonist gremlin in pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 295:L272-84.
6. D'Ippolito G, Diabira S, Howard GA, Roos BA, Schiller PC. 2006. Low oxygen tension inhibits osteogenic differentiation and enhances stemness of human MIAMI cells. Bone 39:513-522. (Pubitemid 44149268)
7. Ellies DL, Viviano B, McCarthy J, Rey JP, Itasaki N, Saunders S, Krumlauf R. 2006. Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity. J Bone Miner Res 21:1738-1749. (Pubitemid 46141229)
8. Gardner JC, van Bezooijen RL, Mervis B, Hamdy NA, Lowik CW, Hamersma H, Beighton P, Papapoulos SE. 2005. Bone mineral density in sclerosteosis; affected individuals and gene carriers. J Clin Endocrinol Metab 90:6392-6395. (Pubitemid 41759290)
9. Gong Y, Slee RB, Fukai N, Rawadi G, Roman-Roman S, Reginato AM, Wang H, Cundy T, Glorieux FH, Lev D, Zacharin M, Oexle K, Marcelino J, SuwairiW, Heeger S, Sabatakos G, Apte S, Adkins WN, Allgrove J, Arslan-Kirchner M, Batch JA, Beighton P, Black GC, Boles RG, Boon LM, Borrone C, Brunner HG, Carle GF, Dallapiccola B, De Paepe A, Floege B, Halfhide ML, Hall B, Hennekam RC, Hirose T, Jans A, Juppner H, Kim CA, Keppler-Noreuil K, Kohlschuetter A, LaCombe D, Lambert M, Lemyre E, Letteboer T, Peltonen L, Ramesar RS, Romanengo M, Somer H, Steichen-Gersdorf E, Steinmann B, Sullivan B, Superti-Furga A, Swoboda W, van den Boogaard MJ, Van Hul W, Vikkula M, Votruba M, Zabel B, Garcia T, Baron R, Olsen BR, Warman ML. 2001. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107:513-523. (Pubitemid 33152786)
10. Gonzalez Suarez I, Fernandez Martin JL, Naves Diaz M, Cannata Andia JB. 2003. Effect of desferrioxamine and deferiprone on osteocalcin secretion in osteoblast-type cells. Nefrologia 23(Suppl 2):27-31.
11. Kamiya N, Ye L, Kobayashi T, Mochida Y, Yamauchi M, Kronenberg HM, Feng JQ, Mishina Y. 2008. BMP signaling negatively regulates bone mass through sclerostin by inhibiting the canonical Wnt pathway. Development 135:3801-3811.
12. Kamiya N, Kobayashi T, Mochida Y, Yu PB, Yamauchi M, Kronenberg HM, Mishina Y. 2009. Wnt Inhibitors Dkk1 and Sost are downstream targets of BMP signaling through the Type IA receptor (BMPRIA) in Osteoblasts. J Bone Miner Res (e-pub ahead of print).
13. Kane R, Godson C, O'Brien C. 2008. Chordin-like 1, a bone morphogenetic protein-4 antagonist, is upregulated by hypoxia in human retinal pericytes and plays a role in regulating angiogenesis. Mol Vis 14:1138-1148. (Pubitemid 351917369)
14. Keller H, Kneissel M. 2005. SOST is a target gene for PTH in bone. Bone 37:148-158. (Pubitemid 40962421)
15. Kusu N, Laurikkala J, Imanishi M, Usui H, Konishi M, Miyake A, Thesleff I, Itoh N. 2003. Sclerostin is a novel secreted osteoclast-derived bone morphogenetic protein antagonist with unique ligand specificity. J Biol Chem 278:24113-24117. (Pubitemid 36830246)
16. Leupin O, Kramer I, Collette NM, Loots GG, Natt F, Kneissel M, Keller H. 2007. Control of the SOST bone enhancer by PTH using MEF2 transcription factors. J Bone Miner Res 22:1957-1967. (Pubitemid 351229312)
17. Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, Harris SE, Wu D. 2005. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem 280:19883-19887. (Pubitemid 41379516)
18. Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, D'Agostin D, Kurahara C, Gao Y, Cao J, Gong J, Asuncion F, Barrero M, Warmington K, Dwyer D, Stolina M, Morony S, Sarosi I, Kostenuik PJ, Lacey DL, Simonet WS, Ke HZ, Paszty C. 2008. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 23:860-869. (Pubitemid 351768804)
19. Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J, Gao Y, Shalhoub V, Tipton B, Haldankar R, Chen Q, Winters A, Boone T, Geng Z, Niu QT, Ke HZ, Kostenuik PJ, Simonet WS, Lacey DL, Paszty C. 2009. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 24:578-588.
20. Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25:402-408. (Pubitemid 34164012)
21. Loots GG, Kneissel M, Keller H, Baptist M, Chang J, Collette NM, Ovcharenko D, Plajzer-Frick I, Rubin EM. 2005. Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res 15:928-935. (Pubitemid 40994212)
22. Naves Diaz ML, Elorriaga R, Canteros A, Cannata Andia JB. 1998. Effect of desferrioxamine and deferiprone (L1) on the proliferation of MG-63 bone cells and on phosphatase alkaline activity. Nephrol Dial Transplant 13(Suppl 3):23-28.
23. O'Brien CA, Plotkin LI, Galli C, Goellner JJ, Gortazar AR, Allen MR, Robling AG, Bouxsein M, Schipani E, Turner CH, Jilka RL, Weinstein RS, Manolagas SC, Bellido T. 2008. Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS ONE 3:e2942.
24. Ontiveros C, Irwin R, Wiseman RW, McCabe LR. 2004. Hypoxia suppresses runx2 independent of modeled microgravity. J Cell Physiol 200:169-176. (Pubitemid 38880202)
25. Papanicolaou SE, Phipps RJ, Fyhrie DP, Genetos DC. 2009. Modulation of sclerostin expression by mechanical loading and bone morphogenetic proteins in osteogenic cells. Biorheology 46:389-399.
26. Park JH, Park BH, Kim HK, Park TS, Baek HS. 2002. Hypoxia decreases Runx2/Cbfa1 expression in human osteoblast-like cells. Mol Cell Endocrinol 192:197-203. (Pubitemid 34667237)
27. Partridge NC, Alcorn D, Michelangeli VP, Ryan G, Martin TJ. 1983. Morphological and biochemical characterization of four clonal osteogenic sarcoma cell lines of rat origin. Cancer Res 43:4308-4314. (Pubitemid 13044057)
28. Qu ZH, Zhang XL, Tang TT, Dai KR. 2008. Promotion of osteogenesis through beta-catenin signaling by desferrioxamine. Biochem Biophys Res Commun 370:332-337.
29. Salim A, Nacamuli RP, Morgan EF, Giaccia AJ, Longaker MT. 2004. Transient changes in oxygen tension inhibit osteogenic differentiation and Runx2 expression in osteoblasts. J Biol Chem 279:40007-40016. (Pubitemid 39258275)
30. Schipani E, Ryan HE, Didrickson S, Kobayashi T, Knight M, Johnson RS. 2001. Hypoxia in cartilage: HIF-1alpha is essential for chondrocyte growth arrest and survival. Genes Dev 15:2865-2876. (Pubitemid 33042056)
31. Semenov MV, He X. 2006. LRP5 mutations linked to high bone mass diseases cause reduced LRP5 binding and inhibition by SOST. J Biol Chem 281:38276-38284. (Pubitemid 46043307)
32. Silvestrini G, Ballanti P, Leopizzi M, Sebastiani M, Berni S, Di Vito M, Bonucci E. 2007. Effects of intermittent parathyroid hormone (PTH) administration on SOST mRNA and protein in rat bone. J Mol Histol 38:261-269. (Pubitemid 47106897)
33. Sutherland MK, Geoghegan JC, Yu C, Winkler DG, Latham JA. 2004. Unique regulation of SOST, the sclerosteosis gene, by BMPs and steroid hormones in human osteoblasts. Bone 35:448-454. (Pubitemid 38953192)
34. Takahashi K, Kogaki S, Matsushita T, Nasuno S, Kurotobi S, Ozono K. 2007. Hypoxia induces alteration of bone morphogenetic protein receptor signaling in pulmonary artery endothelial cell. Pediatr Res 61:392-397. (Pubitemid 46569289)
35. Tuncay OC, Ho D, Barker MK. 1994. Oxygen tension regulates osteoblast function. Am J Orthod Dentofacial Orthop 105:457-463.
36. Utting JC, Robins SP, Brandao-Burch A, Orriss IR, Behar J, Arnett TR. 2006. Hypoxia inhibits the growth, differentiation and bone-forming capacity of rat osteoblasts. Exp Cell Res 312:1693-1702. (Pubitemid 43776006)
37. van Bezooijen RL, Roelen BA, Visser A, van der Wee-Pals L, de Wilt E, Karperien M, Hamersma H, Papapoulos SE, ten Dijke P, Lowik CW. 2004. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med 199:805-814.
38. van Bezooijen RL, Deruiter MC, Vilain N, Monteiro RM, Visser A, van der Wee-Pals L, van Munsteren CJ, Hogendoorn PC, Aguet M, Mummery CL, Papapoulos SE, Ten Dijke P, Lowik CW. 2007. SOST expression is restricted to the great arteries during embryonic and neonatal cardiovascular development. Dev Dyn 236:606-612. (Pubitemid 46233305)
39. Wan C, Gilbert SR, Wang Y, Cao X, Shen X, Ramaswamy G, Jacobsen KA, Alaql ZS, Eberhardt AW, Gerstenfeld LC, Einhorn TA, Deng L, Clemens TL. 2008. Activation of the hypoxia-inducible factor-1alpha pathway accelerates bone regeneration. Proc Natl Acad Sci USA 105:686-691. (Pubitemid 351171769)
40. Wang Y, Wan C, Deng L, Liu X, Cao X, Gilbert SR, Bouxsein ML, Faugere MC, Guldberg RE, Gerstenfeld LC, Haase VH, Johnson RS, Schipani E, Clemens TL. 2007. The hypoxia-inducible factor alpha pathway couples angiogenesis to osteogenesis during skeletal development. J Clin Invest 117:1616-1626. (Pubitemid 46871346)
41. Wergedal JE, Veskovic K, Hellan M, Nyght C, Balemans W, Libanati C, Vanhoenacker FM, Tan J, Baylink DJ, Van Hul W. 2003. Patients with Van Buchem disease, an osteosclerotic genetic disease, have elevated bone formation markers, higher bone density, and greater derived polar moment of inertia than normal. J Clin Endocrinol Metab 88:5778-5783. (Pubitemid 38033050)
42. Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, Shpektor D, Jonas M, Kovacevich BR, Staehling-Hampton K, Appleby M, Brunkow ME, Latham JA. 2003. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. Embo J 22:6267-6276. (Pubitemid 37522584)
43. Winkler DG, Sutherland MS, Ojala E, Turcott E, Geoghegan JC, Shpektor D, Skonier JE, Yu C, Latham JA. 2005. Sclerostin inhibition of Wnt-3a-induced C3H10T1/2 cell differentiation is indirect and mediated by bone morphogenetic proteins. J Biol Chem 280:2498-2502. (Pubitemid 40189350)
44. Zahm AM, Bucaro MA, Srinivas V, Shapiro IM, Adams CS. 2008. Oxygen tension regulates preosteocyte maturation andmineralization. Bone 43:25-31.